Abstract：
BACKGROUND: Concise patient-reported outcome (PRO) instruments addressing the consequences of facial acne vulgaris (AV) on patients’ functioning and activities of daily living (ADL) are needed.
METHODS: A 12-week, single-arm, prospective cohort study was conducted in patients ≥9 years old with moderate/severe non-nodular facial AV prescribed sarecycline as part of usual care. The primary endpoint included AV-specific patient- and caregiver-reported outcomes assessed with the expert panel questionnaire (EPQ, developed by 10 experts using a Delphi method) in patients (>12 years) and caregivers (for patients 9-11 years). Additional assessments included parental/caregiver perspectives on children’s AV.
RESULTS: A total of 253 patients completed the study. Following 12-weeks of treatment, there were significant (P ≤.0001) changes from baseline in the proportion of patients responding that they never or rarely: felt angry (31.6%), worried about AV worsening (28.9%), had thoughts about AV (20.9%), had a certain level of worries about AV (38.7%), altered their social media/selfie activity (23.7%), had an impact on real-life plans due to AV (22.9%), made efforts to hide AV (21.3%), felt picked-on/judged due to AV (15.0%), were concerned about their ability to reach future goals due to AV (13.8%), or had sleep impacted due to AV (18.2%). No significant change from baseline was observed for parent/caregiver’s understanding of the child’s AV concerns, from both patient and parent/caregiver perspectives.
CONCLUSIONS: Over 12 weeks of AV management with oral sarecycline, patients reported significant reductions in AV-related effects on emotional/social functioning and ADL as measured by the EPQ, a simple PRO with potential for use in clinical practice. J Drugs Dermatol. 2024;23:1(Suppl 1):s4-11.
METHODS: A 12-week, single-arm, prospective cohort study was conducted in patients ≥9 years old with moderate/severe non-nodular facial AV prescribed sarecycline as part of usual care. The primary endpoint included AV-specific patient- and caregiver-reported outcomes assessed with the expert panel questionnaire (EPQ, developed by 10 experts using a Delphi method) in patients (>12 years) and caregivers (for patients 9-11 years). Additional assessments included parental/caregiver perspectives on children’s AV.
RESULTS: A total of 253 patients completed the study. Following 12-weeks of treatment, there were significant (P ≤.0001) changes from baseline in the proportion of patients responding that they never or rarely: felt angry (31.6%), worried about AV worsening (28.9%), had thoughts about AV (20.9%), had a certain level of worries about AV (38.7%), altered their social media/selfie activity (23.7%), had an impact on real-life plans due to AV (22.9%), made efforts to hide AV (21.3%), felt picked-on/judged due to AV (15.0%), were concerned about their ability to reach future goals due to AV (13.8%), or had sleep impacted due to AV (18.2%). No significant change from baseline was observed for parent/caregiver’s understanding of the child’s AV concerns, from both patient and parent/caregiver perspectives.
CONCLUSIONS: Over 12 weeks of AV management with oral sarecycline, patients reported significant reductions in AV-related effects on emotional/social functioning and ADL as measured by the EPQ, a simple PRO with potential for use in clinical practice. J Drugs Dermatol. 2024;23:1(Suppl 1):s4-11.
摘要：
背景：需要简明的患者报告结果（PRO）工具，以解决面部寻常痤疮（AV）对患者的影响。功能和日常生活活动（ADL）。
方法：12周，单臂,前瞻性队列研究是在≥9岁的患者中进行的，这些患者患有中度/重度非结节性面部房室，作为常规护理的一部分。主要终点包括用专家小组问卷评估的房室特定患者和护理人员报告的结果(EPQ，由10位专家使用Delphi方法开发）在患者（12岁）和护理人员（患者9-11岁）中。其他评估包括父母/照顾者对儿童的看法。
结果：共有253名患者完成了研究。经过12周的治疗，有显著的（P＆le;.0001）变化从基线患者的比例，他们从来没有或很少：感到愤怒（31.6%），担心AV恶化(28.9%)，对AV有想法（20.9%），对AV有一定程度的担忧(38.7%)，改变了他们的社交媒体/自拍活动(23.7%)，由于AV（22.9%），对现实生活中的计划产生了影响，努力隐藏AV(21.3%)，由于AV（15.0%），感觉被选中/判断，由于AV（13.8%），他们担心他们实现未来目标的能力，或因房室感染而影响睡眠（18.2%）。父母/看护人对儿童AV问题的理解与基线相比没有显著变化，从患者和父母/护理人员的角度来看。
结论：在12周的房室治疗中，通过EPQ测量，患者报告对情绪/社会功能和ADL的AV相关影响显着降低，一个简单的PRO在临床实践中使用的潜力。J药物Dermatol.2024；23：1（增刊1）：s4-11。
方法：12周，单臂,前瞻性队列研究是在≥9岁的患者中进行的，这些患者患有中度/重度非结节性面部房室，作为常规护理的一部分。主要终点包括用专家小组问卷评估的房室特定患者和护理人员报告的结果(EPQ，由10位专家使用Delphi方法开发）在患者（12岁）和护理人员（患者9-11岁）中。其他评估包括父母/照顾者对儿童的看法。
结果：共有253名患者完成了研究。经过12周的治疗，有显著的（P＆le;.0001）变化从基线患者的比例，他们从来没有或很少：感到愤怒（31.6%），担心AV恶化(28.9%)，对AV有想法（20.9%），对AV有一定程度的担忧(38.7%)，改变了他们的社交媒体/自拍活动(23.7%)，由于AV（22.9%），对现实生活中的计划产生了影响，努力隐藏AV(21.3%)，由于AV（15.0%），感觉被选中/判断，由于AV（13.8%），他们担心他们实现未来目标的能力，或因房室感染而影响睡眠（18.2%）。父母/看护人对儿童AV问题的理解与基线相比没有显著变化，从患者和父母/护理人员的角度来看。
结论：在12周的房室治疗中，通过EPQ测量，患者报告对情绪/社会功能和ADL的AV相关影响显着降低，一个简单的PRO在临床实践中使用的潜力。J药物Dermatol.2024；23：1（增刊1）：s4-11。
